home / stock / opthf / opthf news

OPTHF News and Press, Optimi Health From 05/10/24

Stock Information
Company Name: Optimi Health
Stock Symbol: OPTHF
Market: OTC
Website: optimihealth.ca
Menu
OPTHF OPTHF Quote OPTHF Short OPTHF News OPTHF Articles OPTHF Message Board
Get OPTHF Alerts

News, Short Squeeze, Breakout and More Instantly...
OPTHF - Optimi Health Provides Corporate Update

VANCOUVER, British Columbia, May 10, 2024 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“ Optimi ” or the “ Company ”), a leading Health Canada licensed GMP psychedelics pharmaceutical manufacturer, specializing in controlle...
OPTHF - Optimi Health Receives Export Permit from Health Canada to Ship MDMA To Tel Aviv University's Institute for Psychedelic Research

VANCOUVER, British Columbia, May 09, 2024 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN), a leading Health Canada licensed GMP psychedelics pharmaceutical manufacturer, specializing in controlled substances such as botanical psilocybin and MDMA, is pleased to re...

OPTHF - Optimi Health and Kwantlen Polytechnic University Applied Genomics Centre Partner to Advance Mushroom Science and Research

VANCOUVER, British Columbia, April 23, 2024 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN), a leading Health Canada licensed psychedelics pharmaceutical manufacturer, is thrilled to announce an innovative research and development partnership with the Kwantlen Polyte...

OPTHF - Optimi Health Achieves Milestone: Completes In-House Production of MDMA Active Pharmaceutical Ingredient (API)

VANCOUVER, British Columbia, April 15, 2024 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN), a leading Health Canada licensed psychedelics pharmaceutical manufacturer, specializing in controlled substances such as natural psilocybin and MDMA, has announced the comple...
OPTHF - Optimi Health Signs Psilocybin Supply Agreement With New Zealand-Based M?tai Medical Research Institute

VANCOUVER, British Columbia, April 09, 2024 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN), a leading Health Canada licensed psychedelics pharmaceutical manufacturer, specializing in controlled substances such as natural psilocybin and MDMA, is proud to announce...

OPTHF - Optimi Health Receives Finished Product Test Results and Certificate Of Analysis for GMP Natural Psilocybin Extract

VANCOUVER, British Columbia, April 02, 2024 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN), a leading Health Canada licensed psychedelics pharmaceutical manufacturer, specializing in controlled substances such as natural psilocybin and MDMA, is pleased to announce t...

OPTHF - Optimi Health Confirms Presenting Sponsorship at the 4th Annual Psychedelic Therapeutics and Drug Development Conference

VANCOUVER, British Columbia, March 28, 2024 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN), a leading Health Canada licensed psychedelics pharmaceutical manufacturer, specializing in controlled substances such as natural psilocybin and MDMA, proudly announces its ro...
OPTHF - Optimi Health to Supply MDMA for Psychedelic Research at Tel Aviv University

VANCOUVER, British Columbia, March 26, 2024 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN), a leading Health Canada licensed psychedelics pharmaceutical manufacturer, specializing in controlled substances such as natural psilocybin and MDMA, is thrilled to annou...

OPTHF - Optimi Announces Closing of First Tranche of Non-Brokered Private Placement

VANCOUVER, British Columbia, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“ Optimi ” or the “ Company ”), a Health Canada licensed drug researcher and formulator specializing in controlled psychedelic substanc...

OPTHF - Psychedelic stocks gain after FDA priority review for MDMA therapy

2024-02-12 12:13:32 ET More on ATAI, COMPASS Pathways, etc. Compass Pathways: Psilocybin Developer A Potentially Intriguing, Contrarian Play Mind Medicine: Positive MM-120 Data Leads To Other 2024 Catalysts De-Risking Psychedelics: Compass Pathways, Cybin And Atai ...
Previous 10 Next 10